Company intelligence / Profile preview

Essenlix

Monmouth Junction, New Jersey, United Statesessenlix.com ↗

Ownership: Private
Employees: ~24
Development stage: Commercial

Overview

Essenlix has developed the iMOST platform—a mobile instant health test solution using nanotechnology and AI to deliver rapid results from a single drop of body fluid. The flagship product iMOST-CBC provides complete blood counts in about a minute with lab-quality accuracy. The technology has undergone years of development and clinical validation but was not yet FDA-cleared as of the last update.

Therapeutic areas: Hematology
Modalities: Device (diagnostic analyzer)Nanotechnology-enabled diagnosticsArtificial intelligence/machine learning-based diagnosticsBiochip (Q-card)Small molecule/protein/cell/nucleic acid detection (platform supports all)
Industry: Pathology

Partnerships

Roche Diagnostics Norway—partnership to implement Essenlix’s iMOST platform for at-home patient testing market in Norway.

Beyond the preview

Go deeper on Essenlix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Essenlix.

Explore the full profile